Los Angeles Capital Management LLC Acquires Shares of 245,695 Puma Biotechnology, Inc. (NASDAQ:PBYI)

Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 245,695 shares of the biopharmaceutical company’s stock, valued at approximately $627,000. Los Angeles Capital Management LLC owned about 0.50% of Puma Biotechnology as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. Frazier Life Sciences Management L.P. increased its holdings in shares of Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Puma Biotechnology by 2.0% during the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock worth $10,366,000 after purchasing an additional 39,239 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Puma Biotechnology by 1.4% in the second quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock valued at $5,715,000 after buying an additional 23,600 shares during the period. Great Point Partners LLC raised its holdings in Puma Biotechnology by 10.6% in the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock valued at $4,846,000 after buying an additional 142,916 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Trading Down 19.1 %

Shares of PBYI stock opened at $2.42 on Friday. The company’s fifty day simple moving average is $2.73 and its two-hundred day simple moving average is $3.24. The stock has a market capitalization of $118.80 million, a price-to-earnings ratio of 5.04 and a beta of 1.09. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the business earned $0.12 earnings per share. As a group, analysts anticipate that Puma Biotechnology, Inc. will post 0.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PBYI. StockNews.com upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, November 8th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.